Scrub Typhus: Re-emergence, Diagnostic Timing and Laboratory Challenges

Introduction

Scrub typhus is a mite-borne acute febrile illness caused primarily by Orientia tsutsugamushi. More than one million infections have been estimated to occur annually, particularly across the Asia-Pacific region, although the true burden remains difficult to measure because diagnostic capacity and surveillance vary widely. Without treatment, 6 to 30% of scrub typhus patients die. [1] [2]

The disease is transmitted by infected larval trombiculid mites, commonly called chiggers. It should be distinguished from epidemic typhus caused by Rickettsia prowazekii and flea-borne or murine typhus caused by Rickettsia typhi; these are biologically and epidemiologically distinct infections with different arthropod vectors. [5]

Clinical illness ranges from uncomplicated fever to severe multisystem disease. A systematic review of historical untreated patient series found a median mortality of 6%, with a very wide range from 0% to 70%; a separate review of treated cases reported a median mortality of approximately 1.4%. These estimates came from heterogeneous studies and should not be interpreted as a fixed risk for an individual patient. Their importance is that scrub typhus is a potentially fatal but treatable infection: delayed recognition can allow progression to pneumonitis or acute respiratory distress syndrome, encephalitis, renal or hepatic failure, hemorrhage and multiorgan dysfunction. [3] [4] [5]

This review focuses on changing geographic recognition, seasonality, clinical presentation, diagnostic timing, laboratory-network challenges, serology, molecular diagnosis, antimicrobial susceptibility and the genomic diversity that may influence future assay design.

Changing geographic footprint and seasonality

Scrub typhus was historically associated with the so-called “tsutsugamushi triangle,” extending across much of South and Southeast Asia, East Asia and northern Australia. Within this broad region, seasonal activity differs markedly. Temperate areas often show autumn peaks, whereas tropical and subtropical settings may experience transmission throughout the year, with local peaks influenced by rainfall, vegetation, chigger activity and human exposure. [1] [5]

The historical geographic model is no longer complete. Autochthonous scrub typhus has been documented in South America, including Chile, and a distinct species, Orientia chuto, was isolated from a patient infected in Dubai. These observations demonstrate that clinically relevant Orientia infections are not confined to the traditional Asia-Pacific range. [6] [7]

Evidence from Africa also supports a broader geographic footprint. A Kenyan study identified scrub-typhus-group antibodies among patients with febrile illness, while investigators in Uganda reported serologic evidence of exposure, seroconversions and a PCR-positive case in severe-infection cohorts. These findings support continued surveillance but also illustrate why serology, molecular detection and clinically confirmed human infection should be distinguished when describing geographic expansion. [8] [9]

North American findings are similarly intriguing. In 2023, investigators detected Orientia DNA in free-living Eutrombicula chiggers collected in North Carolina. A later study detected antibodies reactive to O. tsutsugamushi in a small group of patients with eschars and suspected tick-borne disease. Vector DNA or seroreactivity alone, however, does not establish sustained local human transmission. [10] [11]

Climate and weather may influence chigger activity and seasonal transmission, but geographic patterns are also shaped by land use, host ecology, human exposure, surveillance and diagnostic recognition. Studies have associated temperature, rainfall and humidity with scrub-typhus incidence in some endemic settings, but the strength and direction of these relationships vary by region. [12] [13]

Seasonality should therefore be described regionally rather than as a single universal pattern. Parts of South Asia commonly report monsoon and post-monsoon peaks, while areas of Southeast Asia can experience prolonged or year-round transmission. In parts of Korea, Japan and China, cases often peak in autumn, coinciding with seasonal chigger activity and outdoor or agricultural exposure. Local patterns should be interpreted using regional surveillance rather than extrapolated from another country.

In tropical Far North Queensland, a 21-year study did not find a significant overall seasonal trend for rickettsial disease, even though rickettsial incidence increased over the study period. The authors emphasized that climatic variables are only part of a broader interaction that includes environmental and human factors. [13]

Geographic boundary and laboratory readiness

The geographic boundary is also important from a diagnostic perspective. International travellers can acquire scrub typhus in endemic areas and present after returning to countries where physicians and laboratories encounter the disease only rarely. Imported cases have been reported after travel from endemic regions. In these settings, a careful travel history, recognition of an eschar when present, and a defined reference-laboratory pathway for serology and molecular testing become central to diagnosis. [14] [15]

Regional laboratory strategies across the tsutsugamushi region

South Asia — India, Bangladesh, Nepal and neighbouring regions: a major challenge is access at the level where patients first seek care. The DHR-ICMR framework in India describes a tiered approach in which Weil–Felix may be used as a presumptive test at primary level in resource-limited settings, while IgM ELISA and PCR are more appropriate at higher laboratory tiers and IFA functions mainly as a reference method. Work from Bangladesh also illustrates why serologic cut-offs need local validation against background antibody levels and reference testing. [16] [17]

Southeast Asia — Thailand, Vietnam and neighbouring countries: ELISA, molecular assays and rapid diagnostic tests are used in different combinations, but performance should be assessed against local strain diversity and background antibody levels. Rapid-test sensitivity and specificity cannot be assumed to transfer unchanged from one population to another. [18] [26]

East Asia — Korea, Japan and China: public-health and reference-laboratory networks provide examples of how multiple methods can be organized. Korean laboratory data describe use of PCR-based gene detection and IFA, and Japanese laboratories have used IFA or immunoperoxidase testing while evaluating broader multi-serotype ELISA approaches. In China, nationwide surveillance showed that the median interval from illness onset to diagnosis decreased from seven days in 2006 to five days in 2016; this was an onset-to-diagnosis interval, not a universal laboratory turnaround time. Laboratory-confirmed cases remained uncommon, particularly at primary-care level. [19] [20] [21]

Australia: diagnostic strategies vary by jurisdiction and clinical setting. Molecular testing and serology/IFA may both contribute to confirmation. Rather than assigning a single national turnaround-time figure without a direct laboratory source, interpretation should focus on local access, specimen timing and referral pathways. [13]

Transmission and clinical presentation

After an incubation period that is commonly approximately 7–10 days, scrub typhus usually begins as an acute febrile illness. An eschar may develop at the site where an infected chigger fed and can appear before systemic symptoms. The eschar is a localized necrotic lesion and should not be confused with the macular or maculopapular rash that occurs in some patients. Because eschars are often painless and may occur in the axilla, groin, beneath the breast or under clothing, they can be missed during routine examination. [5]

Other manifestations may include fever, chills, headache, myalgia, lymphadenopathy, gastrointestinal symptoms and altered mental status. Approximately 25–50% of patients develop a rash, which is typically macular or maculopapular. Severe manifestations usually emerge after the first week of untreated illness and can include acute respiratory distress syndrome, encephalitis, pneumonia, renal or liver failure, hemorrhage, multiorgan dysfunction and death. [5]

Clinical severity, mortality and treatment

Mortality is one reason diagnostic delay matters. The systematic review of untreated disease reported a median series mortality of 6% across 89 patient series, although estimates ranged from 0% to 70% because of major differences in geography, case definition, strain, host factors and study design. A review of treated cases reported a substantially lower median mortality of 1.4%, again with wide variation between studies. [3] [4]

Prompt therapy is therefore clinically important, and treatment should not be withheld while awaiting confirmatory testing when scrub typhus is strongly suspected. CDC guidance identifies doxycycline as the treatment of choice for suspected scrub typhus in patients of all ages. [5]

Pregnancy: the 2015 DHR-ICMR guideline lists azithromycin as the drug of choice in pregnant women and specifies 500 mg once daily for five days, stating that doxycycline is contraindicated in pregnancy. Current CDC guidance is more cautious and recommends that treatment during pregnancy be determined in consultation with an infectious-diseases expert. [16] [5]

Disease diagnosis

Relying on eschars in clinical diagnosis

Successful diagnosis remains challenging because no single clinical sign is sufficiently sensitive to exclude disease. Eschar prevalence varies markedly across studies and regions, and absence of an eschar does not rule out scrub typhus. Eschars may be small, painless or located in areas that are not routinely examined, including the groin, axillae and beneath the breast. A deliberate skin examination is therefore useful when the diagnosis is being considered, but laboratory testing and epidemiologic context remain essential. [1] [5]

A key diagnostic error is to treat the eschar and rash as stages of the same lesion. They are separate findings: the eschar is the localized lesion at the chigger feeding site, whereas the rash, when present, is a systemic macular or maculopapular eruption.

Laboratory context

Routine laboratory abnormalities can support clinical suspicion but are not specific. Thrombocytopenia and elevated hepatic transaminases are frequently reported, and severe illness may be accompanied by renal, hepatic, neurologic or respiratory abnormalities. The laboratory pathway therefore depends less on nonspecific chemistry or hematology findings than on correctly timed serology and molecular testing. [5] [36]

Why laboratory diagnosis remains difficult

The difficulty is not caused by one diagnostic test alone. Clinical presentation overlaps with other acute febrile illnesses; the eschar may be absent or hidden; molecular detection is generally most useful early in illness; antibodies become more informative as the immune response develops; and many laboratories receive only a single serum specimen rather than paired acute and convalescent samples. Background antibodies, regional strain diversity and differences in serologic cut-offs add further interpretive complexity. [5] [25] [26]

Primary laboratories and rural health settings face additional operational barriers. IFA requires fluorescent microscopy, antigen preparations and experienced readers; PCR requires molecular infrastructure, trained staff and appropriately timed specimens; and ELISA may be available only at district hospitals or medical colleges. Tests sent to reference laboratories can add transport and referral time while clinicians must make early treatment decisions. [16] [17] [21]

IFA is generally considered a reference serologic method, but a four-fold rise between acute and convalescent specimens provides stronger evidence than a single titre. This makes paired-serum confirmation inherently retrospective. Culture of O. tsutsugamushi is not a routine diagnostic option because the organism is obligately intracellular and culture requires specialized high-containment capability. [5] [25]

Serology, IFA, ELISA and rapid tests

The Weil–Felix OX-K agglutination test continues to be used as a low-cost presumptive test in some resource-limited settings. However, its sensitivity and specificity are poor, and it should not be presented as a definitive diagnostic assay. CDC guidance does not recommend Weil–Felix as a diagnostic assay, while the older DHR-ICMR framework allows it as a presumptive primary-level test in affected resource-limited settings with locally established baseline titres and clinical correlation. [5] [16]

IgM ELISA is widely used in endemic regions because it can be more objective and easier to standardize than reading IFA slides. However, background antibody levels and locally appropriate cut-offs remain important. The Bangladesh experience demonstrates why validation against local populations matters. IFA remains an important reference method but is resource-intensive and is affected by antigen selection and reader interpretation. [17] [26]

Rapid diagnostic tests and lateral-flow formats may improve access where laboratory infrastructure is limited, but product performance should be established in the population and setting where the test will be used. Timing of collection, background antibodies and circulating antigenic variants can influence apparent sensitivity and specificity. [18]

Diagnostic timing: molecular detection versus serology

Molecular detection is generally most useful early in illness and before antibiotic treatment. IgM may become detectable approximately 5–10 days after symptom onset, whereas IgG may take longer. These windows overlap and should be treated as approximate rather than fixed cut-offs. Specimen type, assay design, organism burden, prior exposure and antibiotic treatment all influence performance. [22] [25]

Public Health Ontario reports that single acute serology collected within the first week has sensitivity below 60%; IgM may become detectable 5–10 days after symptom onset and IgG titres may take weeks. PHO also notes that whole-blood PCR sensitivity is lower after antibiotics than before treatment, reinforcing the value of obtaining an appropriate molecular specimen early when feasible. [22]

Canada: referral testing and turnaround time

In Ontario, serum is accepted for serology, while EDTA whole blood, eschar or skin-lesion biopsy, and swabs collected beneath an eschar can be submitted for molecular testing. Specimens are forwarded to the National Microbiology Laboratory. Public Health Ontario lists a turnaround time of up to 21 calendar days from specimen receipt at PHO for both serology and PCR. Acute and convalescent serum specimens collected 2–3 weeks apart may be required for confirmation. [22]

The NML’s direct Guide to Services lists a 15-calendar-day turnaround time for its scrub-typhus real-time PCR and IgM ELISA services. This is not contradictory to PHO’s 21-day figure: the PHO interval is measured from receipt at PHO and includes the provincial referral pathway, whereas the NML figure describes the reference laboratory service itself. [23] [24]

Laboratory leadership and policy priorities

For resource-limited countries, the goal does not need to be placing PCR and IFA in every rural clinic. A more achievable strategy is a tiered diagnostic network in which each level of the laboratory system has a defined role and specimens move rapidly along a standardized referral pathway.

• Primary health centres: train clinicians and laboratory staff to recognize the syndrome, examine deliberately for eschars, document travel and exposure history, record symptom-onset dates and collect appropriately timed specimens.
• District and medical-college laboratories: expand access to IgM ELISA, establish locally appropriate cut-offs, maintain internal quality control and create rapid referral routes for molecular confirmation when early specimens are available.
• Regional and national reference laboratories: provide molecular testing and reference serology, support external quality assessment, investigate discordant results and validate assays against geographically and genetically diverse Orientia strains.
• Rapid diagnostic tests: evaluate sensitivity and specificity locally before large-scale procurement rather than assuming that performance in one population will transfer unchanged to another.
• Measure the diagnostic pathway: track time from symptom onset to specimen collection, specimen receipt to result and referral delays. China’s surveillance data show why onset-to-diagnosis time is a clinically meaningful quality indicator. [21]
• Connect laboratory data to surveillance: link results with geography, season, rainfall, land use, travel history and clinical presentation so that changing transmission patterns can be detected without assuming a single causal driver.

Antigenic diversity and diagnostic interpretation

O. tsutsugamushi is antigenically diverse, with many recognized strains and substantial variation in the 56-kDa type-specific antigen. This diversity complicates serologic standardization because assay antigens, locally circulating strains, background exposure and chosen cut-off titres can all influence interpretation. A recent scoping review documented very wide variation in IFA positivity thresholds, reinforcing the need for regional standardization and paired-serum interpretation where feasible. [2] [26]

Molecular diagnostics and target selection

Molecular testing is particularly valuable early in disease because it can establish infection before a diagnostic antibody response is reliably detectable. The 47-kDa outer-membrane protein antigen/HtrA gene is a well-established target. Jiang and colleagues developed a real-time PCR assay that amplified all 26 O. tsutsugamushi strains evaluated without amplification of the tested Rickettsia species or unrelated bacterial controls. [27]

Other molecular targets include groEL, 16S rRNA and the 56-kDa type-specific antigen gene. The 56-kDa target is useful for genotyping but its diversity can complicate primer and probe design. The groEL gene has also been used in conventional and quantitative PCR assays. [28] [29]

OmpA has been investigated as a more conserved diagnostic target. Evans and colleagues reported high OmpA conservation across the isolates examined and developed PCR primers that amplified ompA from the tested O. tsutsugamushi strains without amplification of negative-control bacteria, supporting its potential as a molecular target while recognizing that clinical validation is less mature than for established targets. [30]

Genomic diversity and future diagnostics

O. tsutsugamushi has an unusually repetitive and rearranged genome. In the six strains examined by long-read sequencing in the Batty study, genome size ranged from approximately 1.93 to 2.47 Mb, with repetitive sequence accounting for roughly one-third to one-half of the genomes examined. Extensive repetitive regions, mobile genetic elements and large-scale genome rearrangements contribute to an unusual genomic architecture. [31]

This architecture matters for diagnostics because fixed-primer assays should be checked against contemporary sequence diversity. Targeted next-generation sequencing could eventually help combine detection with strain characterization, but it is best viewed as a developing complementary approach rather than a replacement for rapid PCR or serology. Cost, low organism burden, specimen quality, enrichment strategy and validated bioinformatic pipelines remain practical constraints. [31]

Antibiotic resistance and treatment challenges

Antimicrobial resistance in O. tsutsugamushi remains an important but debated area. Reports from northern Thailand in the 1990s described patients whose fever resolved more slowly despite doxycycline treatment, and experimental work suggested reduced susceptibility in some isolates. An in-vitro study also found the AFSC-4 strain less susceptible to doxycycline than the Karp strain while azithromycin remained active against both. [32] [33]

Evidence for stable, clinically generalizable doxycycline resistance is nevertheless incomplete. Phuklia and colleagues developed a qPCR-based susceptibility method and tested reference strains together with clinical isolates from Thailand and Laos; their findings did not support doxycycline- or chloramphenicol-resistant isolates among the strains examined. Delayed fever clearance or treatment failure should therefore not automatically be interpreted as antimicrobial resistance. Disease severity, bacterial strain, timing of therapy, drug exposure, host response and alternative diagnoses can also influence clinical response. [34]

Fluoroquinolone susceptibility is another concern. In-vitro testing and sequence analysis have identified a Ser83Leu substitution in the quinolone-resistance-determining region of gyrA, supporting intrinsic reduced fluoroquinolone susceptibility. More surveillance is needed to determine how antimicrobial phenotype varies across circulating strains and whether genomic markers can reliably predict treatment response. [35]

Practical priorities for laboratories

• Record the dates of symptom onset, specimen collection and antibiotic initiation because test interpretation is time-dependent.
• Use molecular testing early in illness when an appropriate specimen is available, while collecting acute serum for baseline serology.
• Do not interpret a single antibody result without considering background seroprevalence, assay cut-off and prior exposure.
• When serologic confirmation is required, obtain a convalescent specimen and evaluate seroconversion or change in titre rather than relying only on one high value.
• Validate molecular targets against genetically diverse strains and reassess primer/probe sequences as new genomes become available.
• Distinguish screening or presumptive tests from confirmatory methods in laboratory reports and clinical guidance.
• For laboratories sending specimens to reference centres, incorporate transport and referral time into expectations for clinical turnaround.

Conclusion

Scrub typhus remains an important diagnostic and public-health challenge because it combines nonspecific febrile illness, variable eschar prevalence, time-dependent laboratory detection, antigenic diversity and uneven access to reference testing. Its recognition beyond historically defined endemic areas also means that travel history and laboratory readiness matter in countries where the disease is uncommon. [1] [5] [6] [7]

Mortality is a central reason to improve this pathway. Historical untreated series show a median mortality of approximately 6%, while treated-case reviews report substantially lower median mortality. Early clinical recognition, prompt appropriate therapy and faster access to reliable diagnostics can reduce the risk that a treatable infection progresses to severe organ dysfunction or death. [3] [4] [5]

Climate and weather may influence chigger activity and seasonal transmission, but they should not be presented as the established primary driver of geographic expansion. Future surveillance should integrate laboratory results with land use, host ecology, human exposure, travel, environmental data and diagnostic recognition to investigate changes in chigger distribution, environmental suitability and scrub-typhus seasonality. [12] [13]

For laboratory leaders and public-health programs, the priority is a connected diagnostic network: appropriate specimen collection at the first point of care, locally validated serology and rapid tests, timely access to molecular confirmation, quality assurance, genomic surveillance and clear communication between primary laboratories, reference centres and surveillance programs.

References

1. Xu G, Walker DH, Jupiter D, Melby PC, Arcari CM. A review of the global epidemiology of scrub typhus. PLoS Negl Trop Dis. 2017;11(11):e0006062. doi:10.1371/journal.pntd.0006062. Source
2. Luce-Fedrow A, Lehman ML, Kelly DJ, et al. A Review of Scrub Typhus (Orientia tsutsugamushi and Related Organisms): Then, Now, and Tomorrow. Trop Med Infect Dis. 2018;3(1):8. doi:10.3390/tropicalmed3010008. Source
3. Taylor AJ, Paris DH, Newton PN. A Systematic Review of Mortality from Untreated Scrub Typhus (Orientia tsutsugamushi). PLoS Negl Trop Dis. 2015;9(8):e0003971. doi:10.1371/journal.pntd.0003971. Source
4. Bonell A, Lubell Y, Newton PN, Crump JA, Paris DH. Estimating the burden of scrub typhus: A systematic review. PLoS Negl Trop Dis. 2017;11(9):e0005838. doi:10.1371/journal.pntd.0005838. Source
5. Centers for Disease Control and Prevention. Clinical Overview of Scrub Typhus. Updated May 15, 2024. Source
6. Weitzel T, Dittrich S, López J, et al. Endemic Scrub Typhus in South America. N Engl J Med. 2016;375(10):954-961. doi:10.1056/NEJMoa1603657. Source
7. Izzard L, Fuller A, Blacksell SD, et al. Isolation of a novel Orientia species (O. chuto sp. nov.) from a patient infected in Dubai. J Clin Microbiol. 2010;48(12):4404-4409. doi:10.1128/JCM.01526-10. Source
8. Thiga JW, Mutai BK, Eyako WK, et al. High Seroprevalence of Antibodies against Spotted Fever and Scrub Typhus Bacteria in Patients with Febrile Illness, Kenya. Emerg Infect Dis. 2015;21(4):688-691. doi:10.3201/eid2104.141387. Source
9. Blair PW, Kobba K, Okello S, et al. Evidence of Orientia spp. Endemicity among Severe Infectious Disease Cohorts, Uganda. Emerg Infect Dis. 2024;30(7):1442-1446. doi:10.3201/eid3007.231040. Source
10. Chen K, Travanty NV, Garshong R, et al. Detection of Orientia spp. Bacteria in Field-Collected Free-Living Eutrombicula Chigger Mites, United States. Emerg Infect Dis. 2023;29(8):1676-1679. doi:10.3201/eid2908.230528. Source
11. Abernathy HA, Ursery L, Merdjane BA, Giandomenico DA, Boyce RM. Orientia tsutsugamushi Antibodies in Patients with Eschars and Suspected Tickborne Disease. Emerg Infect Dis. 2025;31(11):2187-2190. doi:10.3201/eid3111.250763. Source
12. D’Cruz S, Sreedevi K, Lynette C, Gunasekaran K, et al. Climate influences scrub typhus occurrence in Vellore, Tamil Nadu, India: analysis of a 15-year dataset. Sci Rep. 2024;14:1532. doi:10.1038/s41598-023-49333-5. Source
13. Fairhead LJ, Smith S, Sim BZ, Stewart AGA, Stewart JD, Binotto E, et al. The seasonality of infections in tropical Far North Queensland, Australia: A 21-year retrospective evaluation of the seasonal patterns of six endemic pathogens. PLoS Glob Public Health. 2022;2(5):e0000506. doi:10.1371/journal.pgph.0000506. Source
14. Vliegenthart-Jongbloed K, de Mendonça Melo M, Slobbe L, Beersma MFC, van Genderen PJJ. Imported scrub typhus in The Netherlands. Travel Med Infect Dis. 2013;11(3):197-199. PMID:23009943. Source
15. Matsumura Y, Shimizu T. Imported scrub typhus contracted in Myanmar. Kansenshogaku Zasshi. 2009;83(3):256-260. PMID:19522310. Source
16. Rahi M, Gupte MD, Bhargava A, Varghese GM, Arora R. DHR-ICMR Guidelines for Diagnosis & Management of Rickettsial Diseases in India. Indian J Med Res. 2015;141(4):417-422. doi:10.4103/0971-5916.159279. Source
17. Blacksell SD, Kingston HWF, Tanganuchitcharnchai A, et al. Diagnostic Accuracy of the InBios Scrub Typhus Detect™ ELISA for the Detection of IgM Antibodies in Chittagong, Bangladesh. Trop Med Infect Dis. 2018;3(3):95. doi:10.3390/tropicalmed3030095. Source
18. Acharya V, Patro S, Aggarwal K, Dash RK, Patnaik S, Pathi BK. Comparative Analysis of Scrub Typhus Rapid Kits and Their Relevance in Screening and Diagnosis. Cureus. 2025;17(6):e85413. doi:10.7759/cureus.85413. Source
19. Lee KA, Gill B, Kim HS, Yoo J. Analysis of Laboratory Diagnostic Tests for Scrub Typhus from 2019 to 2023. Public Health Wkly Rep. 2024;17(49):2177-2196. doi:10.56786/PHWR.2024.17.49.1. Source
20. Ogawa M, Satoh M, Saijo M, Ando S. Evaluation of a broad-ranging and convenient enzyme-linked immunosorbent assay using the lysate of infected cells with five serotypes of Orientia tsutsugamushi. BMC Microbiol. 2017;17:7. doi:10.1186/s12866-016-0910-5. Source
21. Xin HL, Yu JX, Hu MG, et al. Evaluation of scrub typhus diagnosis in China: analysis of nationwide surveillance data from 2006 to 2016. Infect Dis Poverty. 2019;8:59. doi:10.1186/s40249-019-0566-0. Source
22. Public Health Ontario. Orientia tsutsugamushi (Scrub Typhus): laboratory testing information. Accessed August 20, 2026. Source
23. National Microbiology Laboratory, Public Health Agency of Canada. Guide to Services: Orientia tsutsugamushi Molecular Detection by Real-Time PCR. Accessed August 20, 2026. Source
24. National Microbiology Laboratory, Public Health Agency of Canada. Guide to Services: Orientia tsutsugamushi ELISA IgM. Accessed August 20, 2026. Source
25. Janardhanan J, Trowbridge P, Varghese GM. Diagnosis of scrub typhus. Expert Rev Anti Infect Ther. 2014;12(12):1533-1540. doi:10.1586/14787210.2014.974559. Source
26. Le KK, Saraswati K, Wongsantichon J, Day NPJ, Blacksell SD. Diagnostic heterogeneity in scrub typhus serology: A scoping review of IFA thresholds and regional standardisation needs (2005–2024). PLoS Negl Trop Dis. 2025;19(10):e0013540. doi:10.1371/journal.pntd.0013540. Source
27. Jiang J, Chan TC, Temenak JJ, Dasch GA, Ching WM, Richards AL. Development of a quantitative real-time polymerase chain reaction assay specific for Orientia tsutsugamushi. Am J Trop Med Hyg. 2004;70(4):351-356. PMID:15100446. Source
28. Park HS, Lee JH, Jeong EJ, et al. Rapid and simple identification of Orientia tsutsugamushi from other group rickettsiae by duplex PCR assay using groEL gene. Microbiol Immunol. 2005;49(6):545-549. doi:10.1111/j.1348-0421.2005.tb03760.x. Source
29. Paris DH, Aukkanit N, Jenjaroen K, Blacksell SD, Day NP. A highly sensitive quantitative real-time PCR assay based on the groEL gene of contemporary Thai strains of Orientia tsutsugamushi. Clin Microbiol Infect. 2009;15(5):488-495. doi:10.1111/j.1469-0691.2008.02671.x. Source
30. Evans SM, Adcox HE, VieBrock L, et al. Outer Membrane Protein A Conservation among Orientia tsutsugamushi Isolates Suggests Its Potential as a Protective Antigen and Diagnostic Target. Trop Med Infect Dis. 2018;3(2):63. doi:10.3390/tropicalmed3020063. Source
31. Batty EM, Chaemchuen S, Blacksell S, Richards AL, Paris D, Bowden R, et al. Long-read whole genome sequencing and comparative analysis of six strains of the human pathogen Orientia tsutsugamushi. PLoS Negl Trop Dis. 2018;12(6):e0006566. doi:10.1371/journal.pntd.0006566. Source
32. Watt G, Chouriyagune C, Ruangweerayud R, et al. Scrub typhus infections poorly responsive to antibiotics in northern Thailand. Lancet. 1996;348(9020):86-89. doi:10.1016/S0140-6736(96)02501-9. Source
33. Strickman D, Sheer T, Salata K, et al. In vitro effectiveness of azithromycin against doxycycline-resistant and -susceptible strains of Rickettsia tsutsugamushi, etiologic agent of scrub typhus. Antimicrob Agents Chemother. 1995;39(11):2406-2410. doi:10.1128/AAC.39.11.2406. Source
34. Phuklia W, Panyanivong P, Sengdetka D, et al. Novel high-throughput screening method using quantitative PCR to determine the antimicrobial susceptibility of Orientia tsutsugamushi clinical isolates. J Antimicrob Chemother. 2019;74(1):74-81. doi:10.1093/jac/dky402. Source
35. Tantibhedhyangkul W, Angelakis E, Tongyoo N, et al. Intrinsic fluoroquinolone resistance in Orientia tsutsugamushi. Int J Antimicrob Agents. 2010;35(4):338-341. doi:10.1016/j.ijantimicag.2009.11.019. Source
36. Sonthayanon P, Chierakul W, Wuthiekanun V, et al. Association of high Orientia tsutsugamushi DNA loads with disease of greater severity in adults with scrub typhus. J Clin Microbiol. 2009;47:430-434. Source

Copyright and Use

© 2026 Alligen.org. All rights reserved. Unless otherwise indicated, the original written content and original graphics published in this article are owned by Alligen.org. Brief quotations may be used with appropriate attribution and a link to the original article, subject to applicable copyright law.

Disclaimer

The information published by Alligen.org is provided for educational, scientific, and informational purposes only. It is not intended to constitute medical advice, diagnosis, treatment recommendations, legal advice, or regulatory guidance.